Mr. Clayton Fisher reports
NEW WAVE HOLDINGS CORP FORMS PSYCHEDELIC RESEARCH ADVISORY BOARD AND APPOINTS DR. RICHARD KNOWLES
New Wave Holdings Corp. (formerly New Wave Esports Corp.) is an investment issuer focused on the burgeoning psychedelic and e-sports sectors. In the psychedelic sector, New Wave Holdings, focusing on active psychedelic compounds and functioning mushroom product lines and developing an intellectual property portfolio focusing on psilocybin, LSD, MDMA and ketamine-derived treatments for neuropsychiatric diseases, has brought on Dr. Richard Knowles, PhD, to lead its psychedelic research advisory board.
New Wave Holdings, through its investment in Anahit Therapeutics Ltd., will focus on active psychedelic compounds, functioning mushroom product lines derived from lion's mane, reishi and cordyceps mushrooms, and developing an IP portfolio focused on psilocybin, LSD, MDMA and ketamine-derived treatments for neuropsychiatric diseases (addiction, depression, anxiety and posttraumatic stress disorder). The company is developing a series of medicinal mushroom health products for the pharmaceutical and nutraceutical industries.
The company is pleased to announce that Dr. Knowles has agreed to play a key role on the psychedelic research advisory board. His role will include guiding and conducting research that supports the company's goal of development and commercialization of psychedelic-compound-derived neuropsychiatric treatments, introducing new psilocybin, ketamine, MDMA and LSD research initiatives, assisting in the development of new IP and acting as a liaison to key industry players. The advisory board will evaluate the potential positive effects its medicinal mushroom formulations could have on individuals suffering from indications, such as anxiety/depression and posttraumatic stress disorder, bereavement, and emotional disturbances, as well as stress and substance abuse disorders.
Dr. Richard Knowles, PhD, licensed psychologist
Dr. Knowles holds a PhD in clinical psychology and is a licensed psychologist (PSY 29060) trained at Sofia University. He also holds a master's degree in transpersonal psychology and a BA in psychology, philosophy and anthropology. He has clinical training in psychopathology assessment and diagnosis, psychometric assessment, hypnotherapy, biofeedback, and transpersonal psychology (focusing on existential/humanistic and spiritual concerns with a holistic view of treatment). He also works with the Multidisciplinary Association for Psychedelic Studies (MAPS) in its MDMA-assisted PTSD treatment program. Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.
Stock option grant
In connection with the appointment of Dr. Knowles, the board has granted him 300,000 stock options exercisable at 35 cents for a term of three years. These options will have certain vesting requirements as imposed by the board of directors.
About New Wave Holdings Corp.
New Wave Holdings is an investment issuer focused on the burgeoning psychedelic and e-sports sectors. In the psychedelic sector, New Wave will focus on active psychedelic compounds, functioning mushroom product lines, and developing an IP portfolio focusing on psilocybin, LSD, MDMA and ketamine-derived treatments for neuropsychiatric diseases.
We seek Safe Harbor.
© 2020 Canjex Publishing Ltd. All rights reserved.